The Role of Biomarkers in Distinguishing Infectious From Non-Infectious Diseases

1 Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47:1181–1247. Search in Google Scholar

2 Devkota BP. C-reactive protein, Reference Range, Interpretation, Collection and Panels. Medscape. 2022. Accessed on: December 2023. Available at: https://emedicine.medscape.com/article/2086909-overview Search in Google Scholar

3 Sproston NR, Ashworth JJ. 'Role of C-reactive protein at sites of inflammation and infection', Frontiers in Immunology. 2018;9. Search in Google Scholar

4 Rajab IM, Hart PC, Potempa LA. 'How C-reactive protein structural isoforms with distinctive bioactivities affect disease progression'. Frontiers in Immunology. 2020;11. Search in Google Scholar

5 Binnie A, Lage J, Dos Santos CC. How can biomarkers be used to differentiate between infection and non-infectious causes of inflammation? Evidence-Based Practice of Critical Care. 2020:319-324.e1 Search in Google Scholar

6 Claessens YE, Debray MP, Tubach F et al. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am J Respir Crit Care Med. 2015;192: 974–982. Search in Google Scholar

7 Petel D, Winters N, Gore GC, et al. Use of C-reactive protein to tailor antibiotic use: a systematic review and meta-analysis. BMJ Open. 2018;8(12):e022133. Search in Google Scholar

8 Torres A, Artigas A, Ferrer R. Biomarkers in the ICU: less is more? No. Intensive Care Med. 2021;47:97–100. Search in Google Scholar

9 Póvoa P, Martin-Loeches I, Ramirez P, et al. Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study. Ann Intensive Care. 2016;6(1):32. Search in Google Scholar

10 Tan M, Lu Y, Jiang H et al. The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis: a systematic review and meta-analysis. J Cell Biochem. 2019;120:5852–5859. Search in Google Scholar

11 Hertz FB, Ahlström MG, Bestle MH, et al. Early Biomarker-Guided Prediction of Bloodstream Infection in Critically Ill Patients: C-Reactive Protein, Procalcitonin, and Leukocytes. Open Forum Infect Dis. 2022;14;9 (10): ofac467. Search in Google Scholar

12 Hattori T, Nishiyama H, Kato H, et al. Clinical value of procalcitonin for patients with suspected bloodstream infection. Am J Clin Pathol. 2014;141(1):43-51. Search in Google Scholar

13 Ljungström L, Pernestig AK, Jacobsson G, Andersson R, Usener B, Tilevik D. Diagnostic accuracy of procalcitonin, neutrophil-lymphocyte count ratio, C-reactive protein, and lactate in patients with suspected bacterial sepsis. PLoS One. 2017;12(7):e0181704. Search in Google Scholar

14 Oksuz L, Somer A, Salman N, Erk O, Gurler N. Procalcitonin and C-reactive protein in differantiating to contamination from bacteremia. Braz J Microbiol. 2015;45(4):1415-21. Search in Google Scholar

15 Isaacman DJ, Burke BL. Utility of the serum C-reactive protein for detection of occult bacterial infection in children. Arch Pediatr Adolesc Med. 2002;156(9):905-9. Erratum in: Arch Pediatr Adolesc Med. 2003;157(2):208. PMID: 12197798. Search in Google Scholar

16 Li HX, Liu ZM, Zhao SJ, Zhang D, Wang SJ, Wang YS. Measuring both procalcitonin and C-reactive protein for a diagnosis of sepsis in critically ill patients. J Int Med Res. 2014;42(4):1050-9. Search in Google Scholar

17 Lin CT, Lu JJ, Chen YC, Kok VC, Horng JT. Diagnostic value of serum procalcitonin, lactate, and high-sensitivity C-reactive protein for predicting bacteremia in adult patients in the emergency department. PeerJ. 2017;5:e4094. Search in Google Scholar

18 Qu, R., Hu, L., Ling, Y. et al. C-reactive protein concentration as a risk predictor of mortality in intensive care unit: a multicenter, prospective, observational study. BMC Anesthesiol. 2020;20:292. Search in Google Scholar

19 von Dach E, Albrich WC, Brunel AS, et al. Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients with Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial. JAMA. 2020;323(21):2160-2169. Search in Google Scholar

20 Borges I, Carneiro R, Bergo R, et al. Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers. Crit Care. 2020;24(1):281. Search in Google Scholar

21 Usha Chatterjee and Michelle Butina. Biomarkers of Infection and Inflammation. American Society for Clinical Laboratory Science. 2020;ascls.119.001891; Search in Google Scholar

22 Lin JLJ. Procalcitonin (PCT), Reference Range of Procalcitonin, Interpretation of Procalcitonin Levels, Collection and Panels. 2021. Accessed on: December 2023. Available at: https://emedicine.medscape.com/article/2096589-overview Search in Google Scholar

23 Amour J, Birenbaum A, Langeron O, et al. Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of postoperative infection after vascular surgery. Crit Care Med. 2008;36:1147–1154. Search in Google Scholar

24 Rodriguez AH, Aviles-Jurado FX, Diaz E, et al. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: a CHAID decision-tree analysis. J Infect. 2016;72:143–151. Search in Google Scholar

25 Kamat IS, Ramachandran V, Eswaran H, et al. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and metaanalysis. Infect Dis. 2020;70:538–542. Search in Google Scholar

26 Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilatorassociated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociacion Latino-americana del Torax (ALAT). Eur Respir J. 2017;50:1700582. Search in Google Scholar

27 Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the prohosp randomized controlled trial. JAMA. 2009;302:1059e66. Search in Google Scholar

28 Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18:95e107. Search in Google Scholar

29 Wirz Y, Branche A, Wolff M, et al. Management of respiratory infections with use of procalcitonin: moving toward more personalized antibiotic treatment decisions. ACS Infect Dis. 2017;3:875e9. Search in Google Scholar

30 Meier MA, Branche A, Neeser OL, et al. Procalcitonin-guided antibiotic in patients with positive blood cultures: a patient-level meta-analysis of randomized trials. Clin Infect Dis. 2019;69:388–396. Search in Google Scholar

31 Kim MH, Lim G, Kang SY, Lee WI, Suh JT, Lee HJ. Utility of procalcitonin as an early diagnostic marker of bacteremia in patients with acute fever. Yonsei Med J. 2011;52(2):276-81. Search in Google Scholar

32 Demirdal T, Sen P, Nemli SA. Diagnostic Value of Procalcitonin in Predicting Bacteremia in Intensive Care Unit. Indian J Crit Care Med. 2018;22(2):78-84. Search in Google Scholar

33 Hoeboer SH, van der Geest PJ, Nieboer D, Groeneveld ABJ. The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis. Clin Microbiol Infect. 2015;21:474–481. Search in Google Scholar

34 Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care. 2010;14:203. Search in Google Scholar

35 Suranadi IW, Sinardja CD, Suryadi IA. Role of Procalcitonin in Predicting Mortality and Organ Dysfunction at Intensive Care Admission. Int J Gen Med. 2022;15:4917-4923. Search in Google Scholar

36 Póvoa P, Coelho L, Dal-Pizzol F, et al. How to use biomarkers of infection or sepsis at the bedside: guide to clinicians. Intensive Care Med. 2023;49(2):142-153. Search in Google Scholar

37 Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463-474. Search in Google Scholar